Cambridge Cognition collaborates in virtual study for COVID-19 healthcare workers

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, is collaborating with 4YouandMe and The Center for International Emergency Medical Services to investigate the utility of wearables and mobile phones to measure stress recovery in frontline healthcare workers in the USA caring for COVID-19 positive patients. This virtual study will take place over 6-12 months with up to 500 participants. The project is charity funded and Cambridge Cognition are supporting the project by providing the digital cognitive assessments.

Many healthcare workers worldwide are experiencing high levels of stress as they work on the frontline caring for COVID-19 positive patients. Stress negatively affects the immune system1, which in turn can increase susceptibility to infection. Accurate measurement of stress responses in real-time will be key to better understanding whether stress is a significant risk factor for frontline healthcare workers contracting COVID-19.  

Carrying a mobile phone or wearable is now a habit for most, so the devices are ideally suited to capture subtle fluctuations in wellbeing. The primary goal of the project is to determine whether mobile phones and wearables are a feasible means of detecting and tracking real-time changes in stress and recovery as frontline healthcare workers transition between “on-shift” and “off-shift” with COVID-19 patients. The secondary goal is to determine whether these digital signals can inform risk-detection for COVID-19 infectivity.

Cambridge Cognition is the cognitive assessment partner for this exploratory research project: supporting the identification of clinically meaningful signs of stress, such as mood shifts and changes in cognitive performance.

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

“Tracking stress and recovery for frontline healthcare workers is important research and we are pleased to provide our cognitive assessment expertise for this project. Wearables and mobile phones are unparalleled for tracking real-time responses and Cambridge Cognition has extensive experience in virtual trials such as this. We hope that the environment for healthcare workers may be improved in the future as a result of the objective information gathered in the study.”

Stephen Friend, President and Co-Founder of 4YouandMe, said:

“Our study, that has been enrolling well in the US, is designed to explore how the stressful conditions among frontline healthcare workers might be collected objectively in terms of the immediate and intermediate effects of stress. For several years, we have probed the stress effects on mood, sleep, and cognition. We are thrilled that the well-designed world-class measures we would hope to engage have been provided by Cambridge Cognition. The power and ease of the Cambridge Cognition tools will go a long way to helping us better understand the links between stress and momentary shifts in cognition and in turn hopefully this will allow us to better protect all essential frontline health workers in the near future.”

Reference:  Pruett SB. Stress and the immune system. Pathophysiology. 2003 May 1;9(3):133-53.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition plc investor live webinar today

The interim results for the six months ended 30 June 2022 were released earlier today on 20 September 2022. The Company will conduct a live presentation and Q&A session for investors later today at 5:30 pm BST. The presentation

Cambridge Cognition Holdings

Cambridge Cognition growth in revenue of 31%

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced its unaudited interim results for the six months ended 30 June 2022. The Company followed its strong performance in 2021 with a 31%

Cambridge Cognition Holdings

Cambridge Cognition partnering with the University of Oxford

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it will be collaborating with the University of Oxford by providing cognitive assessments for the Impact of Semaglutide in Amyloid

Cambridge Cognition Holdings

Cambridge Cognition signs two PTSD trial agreements

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced two agreements in a new therapeutic area for the Company, post-traumatic stress disorder.  Most recently, a research agreement was entered into

Cambridge Cognition Holdings

Cambridge Cognition directors buy shares in company

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, announced today that it was informed on the 21st July 2022 of the following purchases of the Company’s ordinary shares by Directors and PDMRs of the

Cambridge Cognition Holdings

Cambridge Cognition to announce preliminary results on 12 April 2022

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, will announce its preliminary results for the year ended 31 December 2021 on 12 April 2022. Cambridge Cognition is a technology company developing digital

No more posts to show